Compare OGEN & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGEN | ALBT |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.3M |
| IPO Year | 2010 | 2015 |
| Metric | OGEN | ALBT |
|---|---|---|
| Price | $0.63 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.0K | ★ 624.1K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.11 | $0.34 |
| 52 Week High | $9.16 | $4.74 |
| Indicator | OGEN | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 38.60 |
| Support Level | $0.61 | $0.34 |
| Resistance Level | $1.02 | $0.51 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 23.38 | 19.94 |
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.